Abstract
Recently, new data have been published on the treatment of metastasized renal cell cancer using targeted therapies. With the approval of the tyrosine kinase inhibitors Sunitinib and Sorafenib, two of these new therapies are now available in clinical practice. This has raised both new opportunities and new questions for the health care professionals involved. Here we report on a consensus conference addressing these questions with answers based on evidence from the recent literature.
Publication types
-
Consensus Development Conference
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / administration & dosage
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / pathology
-
Carcinoma, Renal Cell / surgery
-
Carcinoma, Renal Cell / therapy*
-
Controlled Clinical Trials as Topic
-
Humans
-
Immunologic Factors / therapeutic use
-
Immunotherapy
-
Indoles / administration & dosage
-
Indoles / therapeutic use*
-
Interferon-alpha / therapeutic use
-
Kidney / pathology
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / surgery
-
Kidney Neoplasms / therapy*
-
Meta-Analysis as Topic
-
Neoplasm Metastasis
-
Nephrectomy
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Prognosis
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyridines / administration & dosage
-
Pyridines / therapeutic use*
-
Pyrroles / administration & dosage
-
Pyrroles / therapeutic use*
-
Sorafenib
-
Sunitinib
-
Time Factors
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Immunologic Factors
-
Indoles
-
Interferon-alpha
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Pyrroles
-
Niacinamide
-
Sorafenib
-
Sunitinib